Extending the durability of response is the current focus in cancer immunotherapy with immune checkpoint inhibitors (ICIs). However, factors like non-immunogenic tumor microenvironment (TME) along with aberrant angiogenesis and dysregulated metabolic systems are negative contributors. Hypoxia is a key TME condition and a critical promoter of tumor hallmarks. It acts on immune and non-immune cells within TME in order for promoting immune evasion and therapy resistance. Extreme hypoxia is a major promoter of resistance to the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy. Hypoxia inducible factor-1 (HIF-1) acts as a key mediator of hypoxia and a critical promoter of resistance to the anti-PD-(L)1. Targeting hypoxia or HIF-1 can thus be an effective strategy for reinvigoration of cellular immunity against cancer. Among various strategies presented so far, the key focus is over vascular normalization, which is an approach highly effective for reducing the rate of hypoxia, increasing drug delivery into the tumor area, and boosting the efficacy of anti-PD-(L)1.
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
DeVito, Nicholas C.
论文数: 引用数:
h-index:
机构:
Sturdivant, Michael
Thievanthiran, Balamayooran
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Thievanthiran, Balamayooran
Xiao, Christine
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Xiao, Christine
Plebanek, Michael P.
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Plebanek, Michael P.
Salama, April K. S.
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Salama, April K. S.
Beasley, Georgia M.
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Dept Surg, Div Surg Oncol,Med Ctr, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Beasley, Georgia M.
Holtzhausen, Alisha
论文数: 0引用数: 0
h-index: 0
机构:
Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Holtzhausen, Alisha
Novotny-Diermayr, Veronica
论文数: 0引用数: 0
h-index: 0
机构:
ASTAR, Expt Drug Dev Ctr EDDC, 10 Biopolis Rd,05-01 Chromos, Singapore 138670, SingaporeDuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Novotny-Diermayr, Veronica
Strickler, John H.
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Strickler, John H.
Hanks, Brent A.
论文数: 0引用数: 0
h-index: 0
机构:
Duke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USADuke Univ, Duke Canc Inst, Med Ctr, Dept Med,Div Med Oncol, Durham, NC 27710 USA
机构:
Samsung Med Ctr, Innovat Inst Precis Med, Seoul, South KoreaSamsung Med Ctr, Innovat Inst Precis Med, Seoul, South Korea
Jung, Jaeyun
论文数: 引用数:
h-index:
机构:
Heo, You Jeong
Park, Sehhoon
论文数: 0引用数: 0
h-index: 0
机构:
Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Guam, South KoreaSamsung Med Ctr, Innovat Inst Precis Med, Seoul, South Korea